You are here:

aliskiren (Rasilez)


Following a resubmission

aliskiren (Rasilez) is not recommended for use within NHS Scotland for the treatment of essential hypertension.

Aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, though its effects on mortality and long-term morbidity are currently unknown.

The manufacturer did not present a sufficiently robust clinical or economic analysis to gain acceptance by the SMC for the position sought.

Drug Details

Drug Name: aliskiren (Rasilez)
SMC Drug ID: 462/08
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Essential Hypertension
BNF Category:
Sub Category: 2.6 Nitrates*** calcium-channel blockers*** and other antianginal drugs
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 8 February 2010

Archived Advice

Full submission 12 January 2009
Non submission 12 May 2008